Patent SG-11201906318W-A (SG)
Title: Algorithms and methods for assessing late clinical endpoints in prostate cancer
Inventor: LU RUIXIAO
IPC: C12Q1/6886
Filed: 2018-02-12
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, C12Q 1/6809 (2018.01) C12Q 1/6886 (2018.01) (21) International Application Number: PCT/US2018/017790 (22) International Filing Date: KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (25) Filing Language: (26) Publication Language: (30) Priority Data: 12 February 2018 (12.02.2018) English English 62/458,474 13 February 2017 (13.02.2017) US 62/473,204 17 March 2017 (17.03.2017) US 62/578,622 30 October 2017 (30.10.2017) US (71) Applicant: GENOMIC HEALTH, INC. [US/US]; 301 Penobscot Drive, Redwood City, California 94063 (US). (72) Inventors: LU, Ruixiao; 301 Penobscot Drive, Redwood City, California 94063 (US). CRAGER, Michael; 301 Penobscot Drive, Redwood City, California 94063 (US). ZHANG, Nan; 3234 Mountain Drive, Fremont, California 94555 (US). MADDALA, Tara; 1166 Ribier Court, Sun- nyvale, California 94087 (US). FEBBO, Phillip; 14 Glen Drive, Mill Valley, California 94941 (US). LAWRENCE, Hugh Jeffrey; 6221 Contra Costa Road, Oakland, Califor- nia 94618 (US). (74) Agent: DOHERTY, Elizabeth et al.; McNeill Baur PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massa- chusetts 02140 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, cc (54) Title: ALGORITHMS AND METHODS FOR ASSESSING LATE CLINICAL ENDPOINTS IN PROSTATE CANCER 00 (57) : The present disclosure relates to uses of a multiple gene-expression based Genomic Prostate Score TM (GPS TM ) algo- rithm for assessment of various clinical endpoints in prostate cancer patients, such as risks of clinical recurrence (CR), biochemical O recurrence (BCR), distant metastasis (Mets), and prostate cancer death (PCD). In some embodiments, GPS result is determined for low C and intermediate risk prostate cancer patients in order to assist in determining treatment strategies for those patients. °Ens °nolo olommoiloo mil oimIE (10) International Publication Number WO 2018/148642 Al